Cytori
Therapeutics, Inc. (NASDAQ: CYTX) presented data from two
preclinical studies funded through its contract with the United States
Biomedical Advanced Research and Development Authority (BARDA) at the
2015 American Burn Association Meeting this week in Chicago. The
findings provide greater detail as to how Cytori's cellular therapeutic
improves healing following thermal burn injury even in subjects with
substantial radiation exposure.
"Our data show that Cytori Cell Therapy acts at the cellular and
molecular level to modulate different phases of wound healing thereby
accelerating wound closure in clinically relevant large animal models.
Treatment led to increased angiogenesis, blood vessel maturation, and
deposition of collagen matrix which, along with accelerated
epithelialization led to faster repair," said Dr. John Fraser, Chief
Scientist of Cytori Therapeutics. “These data are consistent with our
prior studies with cells derived from adipose tissue in situations
involving ischemia, inflammation and fibrosis.”
The first presentation titled “Autologous Adipose-Derived
Regenerative Cells (ADRCs) Enhance Wound Healing in a Minipig Model of
Concomitant Radiation and Thermal Burn Injury” establishes in a
preclinical model that Cytori Cell Therapy may be a safe and effective
means for improving burn wound healing in the context of concomitant
radiation exposure. This model comprises radiation exposure sufficient
to damage the bone marrow combined with full thickness burn injury. This
is the first reported large animal model reflecting the clinical
situation of patients exposed to both thermal and radiation injury
following detonation of an improvised nuclear device.
Results demonstrate that delivery of Cytori Cell Therapy accelerated
wound healing with an average 67% increase in blood vessel density, 30%
increase in matrix (collagen) deposition, and a 3.5-fold increase in
epithelialization two weeks after treatment (compared with control
wounds). In addition, molecular analysis demonstrated a 4-fold increase
in E-cadherin expression (a marker of epithelialization) in cell-treated
wounds. Importantly, similar results were observed when the product was
injected directly into the wound or, using a modified formulation, by
intravenous administration. Dr. Dunstana Melo, Director of the Center
for Countermeasures Against Radiation at Lovelace Respiratory Research
Institute (LRRI) noted that, “The knowledge obtained with the
referred model will accelerate the assessment of new medical
countermeasures to be deployed following a mass-casualty event involving
detonation of an Improvised Nuclear Device”.
The second poster presentation titled, “Autologous Adipose-Derived
Regenerative Cells (ADRCs) Seeded in Collagen Scaffold Improves Dermal
Regeneration, Enhancing Early Vascularization and Structural
Organization Following Thermal Burn Injury," shows that seeding the
Cytori cell therapy product onto a widely used dermal substitute after
full thickness burn injury increases depth of wound tissue, collagen
deposition, and wound tissue maturation. Specifically, histological
analysis revealed that blood vessel density was increased by 50% in
wounds receiving cell therapy compared to control. Similarly, the number
of aSMA-positive vessels increased by 60% compared with control. This
quantitative and qualitative improvement in vascularity was associated
with 2-fold increase in tissue thickness and 1.7-fold increase in
collagen I deposition within the wound bed. In addition to these
improvements in wound healing parameters, addition of the cell therapy
product to the scaffold did not impair the ability of the scaffold to
resist wound contraction. Wound contraction is a precursor to the
development of burn scar. One of the functions of the collagen scaffold
is to resist contraction. The data showed no relevant difference in
wound contraction between treated and untreated wounds, which can be
considered supportive of the safety of the cell product. These data
demonstrate that the delivery of the cell therapy product along with
skin substitutes creates the potential for earlier application of
autologous skin grafts thereby reducing patient hospitalization,
recovery time, and outcome following severe thermal burn. “These are
important findings providing new insights for combination of Cytori Cell
Technology with engineered biomaterials for wound healing in severe burn
patients,” said Dr. Mayer Tenenhaus, plastic surgeon at UCSD Burn
Center, specializing in surgery for burns and other traumatic injuries.
Presentations Details:
Abstract
#268
Title: Autologous Adipose-Derived
Regenerative Cells (ADRCs) Seeded in Collagen Scaffold Improves Dermal
Regeneration, Enhancing Early Vascularization and Structural
Organization Following Thermal Burn Injury
Presenter:
Philippe Foubert
Poster: P17. Wounds – Translational Science
I
Link: http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=e752e0e6-8276-4926-aa40-0cc3a2b5e0c9&cKey=ca9c9a72-946f-4fb7-81a1-7e178df8f16a&mKey=%7b71D9A9F0-A27E-4F56-8DF3-AB7E39E05F96%7d
Abstract #273
Title:
Autologous Adipose-Derived Regenerative Cells (ADRCs) Enhance Wound
Healing in a Minipig Model of Concomitant Radiation and Thermal Burn
Injury
Presenter: Philippe Foubert
Poster: P17.
Wounds – Translational Science I
Link: http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=e752e0e6-8276-4926-aa40-0cc3a2b5e0c9&cKey=a7df1c71-1600-494e-9581-a6e84f9af6c7&mKey=%7b71D9A9F0-A27E-4F56-8DF3-AB7E39E05F96%7d
Abstracts are currently available on the American Burn Association
website at http://www.ameriburn.org/47thAnnualMeeting.php
About Cytori Therapeutics, Inc.
Cytori Therapeutics is a late stage cell therapy company developing
autologous cell therapies from adipose tissue to treat a variety of
medical conditions. Data from preclinical studies and clinical trials
suggest that Cytori Cell Therapy™ acts principally by improving blood
flow, modulating the immune system, and facilitating wound repair. As a
result, Cytori Cell Therapy™ may provide benefits across multiple
disease states and can be made available to the physician and patient at
the point-of-care through Cytori’s proprietary solutions.
Cautionary Statement Regarding Forward-Looking
Statements
This press release includes forward-looking statements that involve
known and unknown risks and uncertainties. Some of these risks include
preclinical, clinical and regulatory uncertainties, such as those
associated with the BARDA preclinical studies, including risks in the
collection and results of preclinical data and final clinical outcomes,
and other risks and uncertainties described under the "Risk Factors" in
Cytori's Securities and Exchange Commission Filings, included in our
annual and quarterly reports. There may be events in the future that we
are unable to predict, or over which we have no control, and our
business, financial condition, results of operations and prospects may
change in the future. We assume no responsibility to update or revise
any forward-looking statements to reflect events, trends or
circumstances after the date they are made unless we have an obligation
under U.S. Federal securities laws to do so.
Copyright Business Wire 2015